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Abstract
Background: The use of atypical antipsychotics in schizophrenic patients has been associated with
a risk of weight gain. Similarly, recovery from depression is often followed by improved appetite,
greater food intake and potential increase in weight.
Case presentation: A Caucasian 33-year-old schizophrenic female patient was being treated with
6 mg/day of risperidone and 15 mg/day of clorazepate. She developed depressive symptomatology
and 40 mg/day of fluoxetine was gradually added to her treatment regimen for about 9 months.
After the remission of depression, and the discontinuation of fluoxetine, she experienced an
increase in appetite and subsequently excessive weight gain of 52 kg. Re-administration of
fluoxetine did not reverse the situation. The patient developed diabetes mellitus, which was
successfully controlled with metformin 1700 mg/day. The addition at first of orlistat 360 mg/day
and later of topiramate 200 mg/day has helped her to lose a significant part of the weight gained
(30 kg).
Conclusion:  The case suggests a probable association between the remission of depressive
symptomatology and weight gain in a schizophrenic patient.
Background
The beneficial effects of atypical antipsychotics on posi-
tive symptoms, negative symptoms and cognition in
schizophrenia, as well as the reduced rate of extrapyrami-
dal effects or tardive dyskinesia have led to the wide use of
these drugs in clinical practice [1,2]. On the other hand
their administration might lead to a marked increase in
body weight in addition to metabolic abnormalities [3-
13].
The efficacy of the atypical antipsychotic risperidone- a
combined dopamine D2 and serotonin 5HT2A receptor
antagonist- for both acute and maintenance therapy of
schizophrenic patients is well established [1,14,15].
Regarding the effects of this drug on body weight, in a
meta-analysis evaluating 10 weeks of therapy with atypi-
cal antipsychotics, the mean increase in weight was 2.10
kg [3]. Also, in a double-blind study of schizophrenic and
schizoaffective patients mean weight gain after one year of
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risperidone therapy was 2.3 kg [16]. Furthermore, in the
recent Clinical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) study of chronic schizophrenic patients,
mean increase in weight after 18 months of risperidone
treatment was 0.43 ± 0.49 kg [2]; while in another involv-
ing first-episode schizophrenic patients, mean weight gain
after 2 years of a risperidone regimen was 7.5 ± 0.29 kg
[17]. For a more detailed review of the risk of weight gain
as a result of long-term treatment with risperidone see
also Ref. 12.
Risperidone, compared with olanzapine and clozapine,
also seems to have a lower risk of inducing type 2 diabetes
mellitus [18], although several risperidone-associated
new-onset cases of diabetes have been reported [19].
Reviews of follow-up studies in patients with depression
and in obese, non-depressed patients have shown that the
weight-reducing effects of fluoxetine are transient [4,20]
and that the long-term administration of this drug might
even lead to a gain in body weight [21].
We present the case of a schizophrenic patient who, while
being treated with risperidone, experienced excessive
weight gain and eventually developed diabetes mellitus
after the remission of depression and the discontinuation
of a nine-month treatment with fluoxetine.
Case presentation
A Caucasian 33-year-old married woman had recurrent
delusions of persecution for a period of four years. Diag-
nosis of schizophrenia was established according to DSM-
IV-TR. The severity of her psychotic symptoms was
assessed using the Brief Psychiatric Rating Scale (BPRS).
Family history was negative for schizophrenia and affec-
tive disorder, as well as for obesity and diabetes mellitus.
At the beginning of treatment (BPRS score = 62) 6 mg/day
of risperidone and 15 mg/day of clorazepate were admin-
istered; her body mass index (BMI) at the time was 29.4
(height 165 cm, weight 80 kg, baseline prolactin level =
4.5 ng/ml). After five weeks of risperidone treatment pro-
lactin level was 18.1 ng/ml.
At the end of the first year a significant improvement in
her psychotic symptoms was observed (BPRS score = 29;
prolactin level = 16.1 ng/ml), but also a modest weight
gain (5 kg, BMI reached 31.2). During the second year, she
was fired from her job, spent more time at home and
developed depressive symptomatology; 40 mg/day of
fluoxetine was gradually added to her treatment regimen
for about 9 months. During this time, she gained another
3 kg (BMI = 32.3; prolactin level = 13.4 ng/ml). After the
remission of depression, fluoxetine was discontinued and
she experienced carbohydrate cravings and "binge eating"
episodes, especially during the evening. In the middle of
the third year of treatment, although risperidone was
gradually reduced to 2 mg/day without signs of relapse
(BPRS score = 27), a dramatic increase in body weight was
observed (weight 140 kg, BMI = 51.5; prolactin level =
10.7 ng/ml). All the attempts she made to reduce her
weight by consulting a dietician failed. Since it was after
the remission of depressive symptomatology and the dis-
continuation of fluoxetine that she began gaining exces-
sive weight, fluoxetine (20 mg/day) was re-administered
for few weeks but without any reduction in weight gain.
This suggests that fluoxetine is not related to the patient's
weight gain.
Six months later, she developed polydipsia and polyuria.
Diabetes was diagnosed (her fasting blood glucose level
was 170 mg/dl); thus 1700 mg/day metformin hydrochlo-
ride (an oral hypoglycaemic agent [22]) was prescribed,
and after one month fasting blood glucose level was stabi-
lized within the normal range. At the same time, in collab-
oration with an endocrinologist, 360 mg/day orlistat- a
lipase inhibitor [23] – was administered. Her body weight
was reduced to 120 kg (BMI = 44.1; prolactin level = 8.7
ng/ml) within a period of six months. During the fourth
year of treatment, she was hospitalized for a six-week
period in an attempt to promote further weight loss. On
admission, it was decided to add 200 mg/day topiramate
to her regimen, since it has been reported that topiramate
is an anticonvulsant with mood stabilizing and weight
loss properties [24]. This helped her to lose a further 10 kg
in a six-month period (BMI = 40.4; prolactin levels = 7.2
ng/ml).
The patient never had any abnormalities regarding thy-
roid function or her menstrual cycle (the levels of repro-
ductive hormones were within normal range) during the
four years of treatment. Prolactin levels were not elevated
throughout the treatment with risperidone (range of pro-
lactin levels in our patient under risperidone treatment:
7.2–18.1 ng/ml, normal prolactin levels: 2.5–26.5 ng/
ml). It is worth noting that the patient complied well with
pharmacotherapy.
Conclusion
This is a report on a case of a schizophrenic patient who
experienced excessive weight gain and diabetes mellitus
while being treated with risperidone.
It has been suggested that the average increase in body
weight under risperidone treatment is approximately 2–
2.5 kg, both after 10 weeks and after one year [3,16]; while
after 18 months in chronic schizophrenics and 2 years in
first-episode schizophrenics mean weight gain is 0.43 ±
0.49 kg and 7.5 ± 0.29 kg respectively [2,17]. The risperi-
done-induced weight gain, as a percentage of baseline
body weight, is more pronounced among pre-adolescentsBMC Psychiatry 2006, 6:37 http://www.biomedcentral.com/1471-244X/6/37
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and decreases with advancing age and especially in adults
over the age of 65. In youths and middle-aged adults,
weight increase related to risperidone is greatest during
the first few months of treatment, but in certain cases can
persist beyond one year [25].
In addition to medication type and age, other factors can
influence antipsychotic-induced weight gain, such as
lower BMI and extended duration of treatment [3,12,25-
27]. Studies of olanzapine, risperidone, and quetiapine
have clearly documented that adults whose pre-treatment
BMI is less than 23 have substantially more drug-induced
weight gain than those whose baseline BMI exceeds 27
[25]. Although our patient had a BMI of 29.4 when she
started treatment with risperidone, after 2 1/2 years she
had a substantial further increase in BMI to 51.5 and the
development of diabetes mellitus. Patients under treat-
ment with atypical antipsychotics who have a higher base-
line BMI are at increased risk of diabetes, compared to
patients with a lower BMI [6].
Recovery from depression and from psychotic symptoms
is often associated with improved appetite and better
social functioning, which could lead to greater food intake
and potential weight gain [8,20,27]. Serotonin has been
implicated in the control of eating behavior and body
weight. Stimulants of serotoninergic transmission reduce
food intake and weight gain and increase energy expendi-
ture both in animals and in humans [28]. Fluoxetine was
reported to have anorectic properties [20] and to be pos-
sibly efficacious in reducing binge-eating frequency and
severity in these patients, although both properties of this
drug have been challenged [4,21,29].
Fluoxetine (20 mg/day) was administered again, in the
middle of the third year of treatment, for a period of a few
weeks; but the situation regarding weight gain did not
improve and the drug was once more discontinued.
The administration of orlistat, helped the patient to lose
20 kg of body weight. It is worth noting that this drug has
not been systematically studied in patients with mental
illness or antipsychotic-induced weight gain [24]. The
addition of metformin to the patient regimen did not
result in weight loss. These results are in accordance with
a pilot cross-over study on five female schizophrenic
patients in which this drug did not lead to significant
weight loss compared to placebo [30]. Topiramate has
been suggested as a potential weight-reducing agent when
it is used as an adjunct to an existing mood stabilizer or
antipsychotic therapy, or when it replaces a mood stabi-
lizer [24]. The adition of topiramate 200 mg/day to orli-
stat led to a further reduction of body weight by 10 kg
during the fourth year of treatment with risperidone.
The mechanisms responsible for weight gain in schizo-
phrenic patients are not fully understood. Weight gain is
due to either increased energy intake, decreased energy
expenditure or both, and may also depend on complex
interactions between various drugs [9]. Moreover, factors
affecting the decision to eat are complex and involve envi-
ronmental, cognitive, emotional and behavioral elements
[31].
In schizophrenic patients diets tend to be characterized by
a lack of fruit, vegetables, fibre, an excess of calories and
saturated fat, while physical activity levels appear to be
very low [32]. It is proposed that these people may benefit
by participating in lifestyle management programs early
in the course of the illness [9,11,32]. Our patient pre-
sented increased energy intake, decreased energy expend-
iture and lack of physical activity which possibly
contributed to the excessive increase in weight.
The observation of excessive weight gain in a patient
treated with antipsychotics after the remission of depres-
sion suggests the need for caution. However, further
observations of patients in the same condition should be
carried out in order to clarify whether our findings are rep-
licable.
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